BioNexus Gene Lab Corp. Proceeds from Equity Method Investment, Distribution, Return of Capital
BioNexus Gene Lab Corp. (BGLC) reported Proceeds from Equity Method Investment, Distribution, Return of Capital of $61.41 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital · last filed 2024-04-16
- BioNexus Gene Lab Corp. proceeds from equity method investment, distribution, return of capital for the quarter ending 2023-06-30 was $11.10K, a 8.24% decline year-over-year.
- BioNexus Gene Lab Corp. proceeds from equity method investment, distribution, return of capital for the quarter ending 2023-03-31 was $8.69K, a 20.22% increase year-over-year.
- BioNexus Gene Lab Corp. proceeds from equity method investment, distribution, return of capital for the quarter ending 2022-12-31 was $80.86K, a 844.69% increase year-over-year.
- BioNexus Gene Lab Corp. proceeds from equity method investment, distribution, return of capital for the quarter ending 2022-09-30 was $15.20K.
- BioNexus Gene Lab Corp. proceeds from equity method investment, distribution, return of capital for fiscal 2023 was $61.41K, a 46.78% decline from fiscal 2022.
- BioNexus Gene Lab Corp. proceeds from equity method investment, distribution, return of capital for fiscal 2022 was $115.38K, a 423.59% increase from fiscal 2021.
- BioNexus Gene Lab Corp. proceeds from equity method investment, distribution, return of capital for fiscal 2021 was $22.04K.
| Period end | Proceeds from Equity Method Investment, Distribution, Return of Capital 3 month | Proceeds from Equity Method Investment, Distribution, Return of Capital 6 month | Proceeds from Equity Method Investment, Distribution, Return of Capital 9 month | Proceeds from Equity Method Investment, Distribution, Return of Capital 12 month |
|---|---|---|---|---|
| 2023-12-31 | $61.41K 10-K · filed 2024-04-16 | |||
| 2023-06-30 | $11.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-16 | $19.79K 10-Q · filed 2023-08-16 | $100.64K derived: sum of 3 quarters · filed 2024-04-16 | $115.84K derived: sum of 4 quarters · filed 2024-04-16 |
| 2023-03-31 | $8.69K 10-Q · filed 2023-05-09 | $89.55K derived: sum of 2 quarters · filed 2024-04-16 | $104.75K derived: sum of 3 quarters · filed 2024-04-16 | $116.84K derived: sum of 4 quarters · filed 2024-04-16 |
| 2022-12-31 | $80.86K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $96.06K derived: sum of 2 quarters · filed 2024-04-16 | $108.15K derived: sum of 3 quarters · filed 2024-04-16 | $115.38K 10-K · filed 2024-04-16 |
| 2022-09-30 | $15.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $27.29K derived: sum of 2 quarters · filed 2023-08-16 | $34.52K 10-Q · filed 2022-11-14 | $43.08K derived: sum of 4 quarters · filed 2023-08-16 |
| 2022-06-30 | $12.09K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-16 | $19.32K 10-Q · filed 2023-08-16 | $27.88K derived: sum of 3 quarters · filed 2023-08-16 | |
| 2022-03-31 | $7.23K 10-Q · filed 2023-05-09 | $15.79K derived: sum of 2 quarters · filed 2023-05-09 | ||
| 2021-12-31 | $8.56K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $22.04K 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $13.48K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |